According to the latest data from the National Cancer Center, there were 358,700 new cases of gastric cancer in China and 260,400 deaths in 2022. The incidence of malignant tumors ranked fifth in China, and the mortality rate ranked third.

Gastrin is a gastrointestinal hormone secreted by the G cells of the antrum and duodenum, which plays an important role in regulating the function of the digestive tract and maintaining its structural integrity. In humans, more than 95% of the bioactive gastrin is alpha-aminated gastrin, mainly consisting of two isomers, G-17 and G-34, of which 80%-90% is G-17. G-17 is only secreted by G cells in the gastric antrum, so it is an important indicator of gastric mucosal injury.

Gastrin is a gastrointestinal hormone mainly secreted by the G cells of the antrum and duodenum, which plays an important role in regulating the function of the digestive tract and maintaining its structural integrity.

Pepsinogen (PG) is the precursor of pepsin that divided into pepsinogen I and pepsinogen II according to its biochemical and immunochemical properties. It is mainly secreted by mucous cells, the stomach body and the main cells of the stomach fundus.

Gastric diseases refer to various diseases that affect the structure and function of the stomach, including gastritis, gastric ulcers, and gastric cancer.

Gastric cancer is one of the leading causes of cancer-related deaths worldwide. Early detection and diagnosis are crucial for improving survival rates. In recent years, the combined use of gastric pepsinogen I (PGI), gastric pepsinogen II (PGII), gastrin-17 (G-17) assay kits together with that of Helicobacter pylori (H. pylori) antibodies has shown promise in the field of gastric cancer screening.

Gastric cancer is a global health burden, with high mortality rates due to late-stage diagnoses. However, recent advancements in medical research have led to the development of serological screening tests that had shown promising results in detecting gastric cancer at an early stage.

PG I and PG II are two important biomarkers that are widely used in clinical settings to diagnose and monitor various gastrointestinal diseases. PG I, also known as pepsinogen I, is mainly secreted by the gastric chief cells and is an indicator of the overall gastric secretory function. On the other hand, PG II, or pepsinogen II, is secreted by both the chief and pyloric cells and is primarily used to assess the risk of gastric cancer.

Driven by government support, scientific and technological innovation and market demand, the scale and strength of Chinese biomedical enterprises are continuously growing, domestic medical treatment is gradually recognized in the international market, and more and more Chinese enterprises choose to seek overseas market expansion.

In 2020, there were about 1.1 million new cases of gastric cancer worldwide, ranking at fourth among the causes of deaths of malignant tumors, and about 800,000 deaths because of the gastric cancer yearly. Asia (mainly China) has the highest number of registered gastric cancer cases (approximately 820,000 new cases and 580,00 deaths), with less than 20% survival rate in 5-yearan as estimated.